Reason for request
Inclusion on the list of medicines approved for use by hospitals in the new indication: “treatment of multifocal motor neuropathy (MMN)”.
Clinical Benefit
| Substantial |
The actual benefit provided by TEGELINE in this indication is substantial. |
Clinical Added Value
| important |
The Transparency Committee considers that TEGELINE provides a substantial improvement in actual benefit (IAB II) in patients with multifocal motor neuropathy. |
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
6AuJZh6ydtzdP1fv
